Committed member

BioGeneration Ventures

Daniela Couto, Partner


Europe, UK, US

Funding type

Seed and early stage

Focus areas



Since our inception in 2006, we have managed over €200 million across our four funds. Our first two funds BGV I and BGV II, launched in 2006 and 2012 respectively, have yielded major successes including Dezima Pharma and Acerta Pharma which were sold within three years at multi-billion dollar deal valuations. BGV III is currently holding 12 active portfolio investments. We are actively looking for new seed and early stage investment opportunities in biotech companies for BGV IV launched in April 2020. BGV invests in partnership with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University ), venture capital investors in the Netherlands, the EU and the US.

Contact details